1. Home
  2. LEE vs CUE Comparison

LEE vs CUE Comparison

Compare LEE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEE
  • CUE
  • Stock Information
  • Founded
  • LEE 1890
  • CUE 2014
  • Country
  • LEE United States
  • CUE United States
  • Employees
  • LEE N/A
  • CUE N/A
  • Industry
  • LEE Newspapers/Magazines
  • CUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • LEE Consumer Discretionary
  • CUE Health Care
  • Exchange
  • LEE Nasdaq
  • CUE Nasdaq
  • Market Cap
  • LEE 90.6M
  • CUE 91.9M
  • IPO Year
  • LEE N/A
  • CUE 2018
  • Fundamental
  • Price
  • LEE $12.32
  • CUE $1.35
  • Analyst Decision
  • LEE
  • CUE Strong Buy
  • Analyst Count
  • LEE 0
  • CUE 5
  • Target Price
  • LEE N/A
  • CUE $5.00
  • AVG Volume (30 Days)
  • LEE 30.1K
  • CUE 277.1K
  • Earning Date
  • LEE 02-06-2025
  • CUE 03-10-2025
  • Dividend Yield
  • LEE N/A
  • CUE N/A
  • EPS Growth
  • LEE N/A
  • CUE N/A
  • EPS
  • LEE N/A
  • CUE N/A
  • Revenue
  • LEE $600,264,000.00
  • CUE $9,532,000.00
  • Revenue This Year
  • LEE N/A
  • CUE $73.11
  • Revenue Next Year
  • LEE N/A
  • CUE $11.02
  • P/E Ratio
  • LEE N/A
  • CUE N/A
  • Revenue Growth
  • LEE N/A
  • CUE 149.53
  • 52 Week Low
  • LEE $7.57
  • CUE $0.45
  • 52 Week High
  • LEE $19.63
  • CUE $2.58
  • Technical
  • Relative Strength Index (RSI)
  • LEE 37.54
  • CUE 51.23
  • Support Level
  • LEE $11.50
  • CUE $1.27
  • Resistance Level
  • LEE $13.69
  • CUE $1.50
  • Average True Range (ATR)
  • LEE 0.94
  • CUE 0.13
  • MACD
  • LEE 0.06
  • CUE -0.00
  • Stochastic Oscillator
  • LEE 22.47
  • CUE 61.44

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Share on Social Networks: